Immunotherapy advances in triple-negative breast cancer drive personalized treatments with immune checkpoint inhibitors, ...

The FDA cleared the investigational new drug application for MRANK-106, a dual WEE1/YES1 kinase inhibitor, targeting advanced ...

Waystar's AI-powered AltitudeAI automates claim appeals, aiming to recover billions in denied payments and reduce healthcare ...

For Colorectal Cancer Awareness Month, Scott Kopetz, MD, PhD, FACP, discussed the BREAKWATER trial in metastatic BRAF ...

MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...

The FDA granted orphan drug status to rhenium-186 obisbemeda for treating leptomeningeal metastases in lung cancer.

Andrea Ledford, PharmD, MBA, BCOP, BCSCP, FASHP, FHOPA, discussed a comprehensive pharmacy program presented at the 2025 ACCC ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary ...

An expert discusses the patient case of a man aged 62 years who is newly diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The patient initially presented to the dermatologist with ...

For nearly 20 years, mesothelioma treatment options were limited to a single regimen: pemetrexed with a platinum agent. Now, there are 3 systemic treatment options available. In this video, Hedy Lee ...

Panelists discuss how detailed analyses from KarMMa-3 reveal key insights about ide-cel’s performance across patient subgroups, timing of responses, durability of remissions, and management of adverse ...

An expert discusses the case of a 68-year-old woman diagnosed with primary myelofibrosis. Now Viewing. EP: 1. A 68-Year-Old Woman Diagnosed With Primary Myelofibrosis EP: 2. Molec ...